Important Treatment Considerations With LDL-C– Lowering Therapies

EP: 1.Unmet Needs in the Management of Patients with Hyperlipidemia

EP: 2.Target LDL-C Levels for Patients

EP: 3.Guideline Recommendations for LDL-C Management

EP: 4.Weighing the Benefits and Risks of Statin Therapy

Now Viewing

EP: 5.Important Treatment Considerations With LDL-C– Lowering Therapies

Considerations for Statin Therapy Initiation and Intensification: Clinical Summary

Contraindications and Delayed Statin Initiation

• Absolute contraindications: Active liver disease, pregnancy/lactation, and severe hypersensitivity reactions
• Relative contraindications/caution:
  • Advanced kidney disease (particularly on dialysis)
  • History of statin-associated muscle symptoms
  • High-risk drug interactions (particularly with CYP3A4 inhibitors)
  • Frailty in older patients, especially those with limited life expectancy

Special Population Considerations

Liver Disease

• Baseline liver function tests recommended before initiation
• Mild-to-moderate liver enzyme elevations (less than 3 times the upper limit of normal) no longer considered a contraindication
• Start with lower doses and monitor frequently in compensated liver disease
• Consider withholding in decompensated cirrhosis or acute liver injury

Renal Impairment

• Dose adjustments recommended for more renally cleared statins (e.g., rosuvastatin and pravastatin)
• Increased risk of adverse events in advanced chronic kidney disease and dialysis patients
• Consider risk-benefit ratio carefully in end-stage renal disease as cardiovascular benefit may be attenuated

Older Patients (75 years and older)

• Individualized approach based on comorbidities, life expectancy, and frailty
• Primary prevention benefits less established in those older than 75 years without existing atherosclerotic cardiovascular disease (ASCVD)
• Start with lower doses and more gradual titration
• Greater emphasis on monitoring drug interactions due to polypharmacy

Evolution of LDL-C–Lowering Treatment Patterns

• Shift from target-based to risk-based treatment approach
• Increased use of combination therapy (e.g., statins plusezetimibe, or PCSK9 inhibitors)
• Earlier intensification for high-risk patients not meeting goals
• Greater emphasis on residual risk assessment beyond initial statin therapy

Factors Influencing Intensification Decisions

• Patient characteristics favoring intensification:
  • Established ASCVD, especially with recurrent events
  • Familial hypercholesterolemia
  • Diabetes with target organ damage
  • Multiple uncontrolled risk factors
  • Younger patients with long-term risk exposure
• Considerations tempering intensification:
  • Advanced age with limited life expectancy
  • History of statin intolerance
  • Polypharmacy concerns
  • Patient preference and medication adherence challenges
  • Cost/access barriers to advanced therapies